Aripiprazole is an atypical antipsychotic (dopamine D2 partial agonist) indicated for schizophrenia, bipolar I disorder, adjunctive treatment of major depressive disorder and irritability associated with autistic disorder. We supply it to US manufacturers of tablets, orally disintegrating tablets and oral solution.
Data from PubChem (CID 60795) and FDA’s substance registry
CAS number
129722-12-9
Molecular formula
C23H27Cl2N3O2
Molecular weight
448.4g/mol
FDA UNII
IUPAC name
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
InChIKey
CEUORZQYGODEFX-UHFFFAOYSA-N
- Appearance
- White to off-white crystalline powder.
- Solubility
- Practically insoluble in water.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Has several anhydrous and hydrate crystal forms. State the polymorph and the particle size you developed with.
On the US market
- Reference product
- AbilifyNDA 021436
- Approved ANDAs
- 27 with a marketed product
- Approved forms and strengths
- Tablet 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
- Orally disintegrating tablet 10 mg, 15 mg, 20 mg, 30 mg
- Oral solution 1 mg/mL
- Extended-release injectable suspension 300 mg, 300 mg per vial, 400 mg, 400 mg per vial, 720 mg/2.4 mL, 960 mg/3.2 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com
Sertraline Hydrochloride
Selective serotonin reuptake inhibitor (SSRI)
CAS 79559-97-0Escitalopram Oxalate
Selective serotonin reuptake inhibitor (SSRI)
CAS 219861-08-2Duloxetine Hydrochloride
Serotonin-norepinephrine reuptake inhibitor (SNRI)
CAS 136434-34-9Bupropion Hydrochloride
Norepinephrine-dopamine reuptake inhibitor
CAS 31677-93-7